The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Cancer prognosis remains a lottery dependent on cancer type, disease stage at diagnosis, and personal genetics. While investment in research is at an all‐time high, new drugs are more likely to fail in clinical trials today than in the 1970s. In this review, a summary of current survival statistics in North America is provided, followed by an overview of the modern drug discovery process, classes of models used throughout different stages, and challenges associated with drug development efficiency are highlighted. Then, an overview of the cancer hallmarks that drive clinical progression is provided, and the range of available clinical therapies within the context of these hallmarks is categorized. Specifically, it is found that historically, the development of therapies is limited to a subset of possible targets. This provides evidence for the opportunities offered by novel disease‐relevant in vitro models that enable identification of novel targets that facilitate interactions between the tumor cells and their surrounding microenvironment. Next, an overview of the models currently reported in literature is provided, and the cancer biology they have been used to explore is highlighted. Finally, four priority areas are suggested for the field to accelerate adoption of in vitro tumour models for cancer drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The composition of the tumor microenvironment ( TME , see Glossary) and tumor stromal interactions are major factors that aggravate tumor growth and metastasis, leading to poor clinical outcomes [1 -5].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [5]
In the citing paper
“The surface of synthetic polymers can be modi fi ed to incorporate peptides, such as RGD (Arg-Gly-Asp) peptides or fi brinogen, that promote protein adsorption and cell adhesion [5].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [5]
In the citing paper
“Organoids are grown on a matrix, normally Matrigel or collagen [5,33].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [5]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 257 · Cited by 80
Research works printed but not linked: 12
- Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017, Canadian Cancer Statistics 2017
- Jaffee E., 2016, Cancer Moonshot Blue Ribbon Pannel Report
- Canadian Cancer Society's Advisory Committee on Cancer Statistics, 1987, Canadian Cancer Statistics 1987
- Aitken M., 2016, Global Oncology Trend Report: A Review of 2015 and Outlook to 2020
- Pharmaceutical Research and Manufacturers of America, 2016, 2016 Biopharmaceutical Research Industry Profile
- Isabella Gashaw K. Z., 2014, Drug Target Rev.
- Sittampalam G. S., 2004, Assay Guidance Manual
- Michael G., 2013, Perspect. Sci., 1, 56
- Caicedo‐Carvajal C. E., 2011, J. Tissue Eng., 2011, 362326
- Nakano O., 2001, Cancer Res., 61, 5132
- Dangles‐Marie V., 2003, Cancer Res., 63, 3682
- West G. W., 1980, Cancer Res., 40, 3665
Metadata
- Authors
- Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P.
- Affiliations
- University of Toronto (CA)
- Institute of Biomaterials and Biomedical Engineering University of Toronto 200 College Street Toronto M5S 3E5 Canada
- Corresponding author
- McGuigan, Alison P.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2018-01-19
- Volume
- 7
- Issue
- 8
- Pages
- e1701174-e1701174
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2791956807
- Cited by
- 80
- References
- 257
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 19 · 2021: 15 · 2020: 11 · 2019: 7 · 2018: 7
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Healthcare Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (146469)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- anticancer drug discovery, cancer hallmarks, tumor microenvironment, drug development failure, cancer therapy targets
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Experimental, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? https://app.cochat.ai/papers/10.1002/adhm.201701174
- The paper
- Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018). The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201701174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.